Edition:
United States

Alere Inc (ALR.N)

ALR.N on New York Stock Exchange

50.46USD
18 Sep 2017
Change (% chg)

$0.70 (+1.41%)
Prev Close
$49.76
Open
$50.35
Day's High
$50.47
Day's Low
$50.18
Volume
579,357
Avg. Vol
245,531
52-wk High
$50.58
52-wk Low
$34.41

Select another date:

Mon, Sep 18 2017

BRIEF-Alere announces intent to voluntarily delist Series B Convertible Perpetual Preferred Stock from the NYSE

* Alere announces intent to voluntarily delist Series B Convertible Perpetual Preferred Stock from the NYSE conditioned upon the completion of its acquisition by Abbott

BRIEF-Quidel announces revised agreement for pending acquisition of Alere’s business

* Quidel announces revised agreement for its pending acquisition of Alere’s B-type Naturietic Peptide (BNP) assay business run on Beckman Coulter Analyzers

BRIEF-Abbott extends cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere

* Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere

Alere to face narrowed securities fraud lawsuit

A federal judge has significantly narrowed a shareholder lawsuit accusing Alere Inc and its senior executives of making false and misleading statements in the lead up to the announcement of a deal to sell the diagnostic testing company to Abbott Laboratories Inc.

BRIEF-Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere Inc

* Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere Inc

BRIEF-Alere Inc enters into purchase agreement with Siemens Diagnostics ​‍​

* Says ‍on July 21, 2017, Alere entered into purchase agreement with Siemens Diagnostics Holding II B.V. ​‍​

UPDATE 3-Abbott profit forecast gets a lift from St. Jude integration

* Shares rise as much as 2.8 pct to $50.83 (Adds conference call details; updates shares)

BRIEF-Alere launches Alere iCup Rx Drug Screen

* Alere launches Alere iCup Rx Drug Screen for detecting commonly misused and abused prescription drugs Source text for Eikon: Further company coverage:

BRIEF-Abbott says commences tender offer for Series B preferred stock of Alere

* Abbott commences cash tender offer for all outstanding shares of series b convertible perpetual preferred stock of Alere Inc

BRIEF-Quidel announces definitive agreement to acquire Alere Triage assets

* Quidel Corp - ‍accretive transactions extend Quidel's market leadership and position it for future growth​

Select another date: